CJC-1295 research guide for Vardenis. Covers DAC vs no-DAC forms, half-life differences, purity testing, and how to source quality CJC-1295 for research.
Most researchers searching for CJC-1295 in Vardenis soon discover that local retail options are nearly impossible to find. This matters because CJC-1295 quality ranges widely across the market — from pharmaceutical-grade 99%+ purity to material with significant impurity issues — and the vendor controls every quality variable. The core quality markers for CJC-1295 are HPLC purity ≥98%, molecular identity verified through mass spectrometry, and a bacterial endotoxin panel — all documented in a batch-specific Certificate of Analysis. What follows is a sourcing and quality evaluation guide built specifically around CJC-1295, covering everything a Vardenis researcher needs to source confidently.
How CJC-1295 Works — Mechanisms & Research
CJC-1295 with DAC (Drug Affinity Complex) is a GHRH analogue with an extended half-life achieved through DAC technology that enables covalent binding to albumin. This modification extends the half-life from minutes (for native GHRH) to approximately 6-8 days, creating a sustained elevation in basal GH levels rather than the pulsatile pattern produced by GHRP compounds. This pharmacokinetic distinction is significant for research design: CJC-1295 based on CJC-1295 with DAC produces a different GH secretion pattern than GHRP compounds, with different downstream effects on IGF-1 and protein synthesis. Researchers in Vardenis comparing compounds in this class should account for these pharmacokinetic differences in their experimental design.
Sourcing Research-Grade CJC-1295
Before looking at individual vendors, understand what genuine quality documentation contains — so you can tell whether a COA is complete and credible. Endotoxin testing in the COA is non-negotiable for any injectable research use — endotoxins from gram-negative bacterial contamination can trigger dangerous inflammatory cascades even at trace quantities. Strong quality indicators beyond COA quality: established track record of at least two years, responsive technical support who understand testing methodology, and cold chain packaging that protects product integrity. Hold lyophilised CJC-1295 at freezer temperature (−20°C) until ready to use; reconstitute only the amount needed for the near-term protocol and store the rest at −20°C.
Order CJC-1295 — ships to Vardenis
COA-verified · International tracking · Research grade
As a research compound, CJC-1295 has not been through the clinical trial process required for pharmaceutical approval — its safety profile is characterised by preclinical data and restricted human research data. Temperature excursions — even brief warming above recommended storage temperature — can partially degrade CJC-1295 without visible changes; always maintain cold chain and work with cold-shipped material. Verify the endotoxin level in your CJC-1295 batch COA before any protocol involving administration — look for results expressed as EU/mg or EU/mL and confirm they fall within appropriate thresholds. Protocol documentation — recording exactly what was used, when, and how — is a sound practice for any CJC-1295 protocol that allows any unexpected observations to be properly contextualised.
Frequently Asked Questions
What is the difference between CJC-1295 with DAC and without DAC?
CJC-1295 with DAC uses a lysine-maleimide conjugate to bind covalently to albumin in the bloodstream, extending half-life to ~6-8 days and creating sustained GH elevation. CJC-1295 without DAC (also called Mod GRF 1-29) has a half-life of ~30 minutes and produces acute GH pulses. They produce different GH secretion patterns and have different applications in research.
What purity is required for CJC-1295 research?
CJC-1295 should be ≥98% pure by HPLC. The larger molecular weight of CJC-1295 with DAC (approximately 3647 Da) makes mass spectrometry confirmation particularly important, as impurities may not be obvious on HPLC alone.
What is CJC-1295?
CJC-1295 is a synthetic GHRH (Growth Hormone Releasing Hormone) analogue. The version with DAC (Drug Affinity Complex) has an extended half-life of approximately 6-8 days due to albumin binding. Without DAC, CJC-1295 has a much shorter half-life similar to native GHRH. Both versions stimulate pulsatile GH release via the GHRH receptor.
